Johnson & Johnson Deepens its Long-Term Commitment to Hong Kong Through OASES Strategic Enterprise Collaboration
PR Newswire•22/10/2026•11:53 ET
0
Key Highlights
- ➤Johnson & Johnson selected as Hong Kong OASES Strategic Enterprise
- ➤Partnership targets stronger clinical research and scientific collaboration
- ➤Initiative supports development of future healthcare and life sciences talent
- ➤Company will pursue patient innovation across oncology, immunology and other priority areas
Expert Statements
Donatas Grabliauskas, General Manager, Johnson & Johnson Innovative Medicine Hong Kong & Macau
“We are honored to become an OASES Strategic Enterprise and deepen our longstanding partnership with Hong Kong. This collaboration reflects a shared commitment to advancing health and medical innovation, strengthening research and developing the next generation of healthcare talent. By working alongside the HKSAR Government and partners across the healthcare ecosystem, we hope to harness the best of Hong Kong's strengths and Johnson & Johnson's global expertise to advance health innovation and make a meaningful difference in the lives of patients, families and communities across Hong Kong.”
Johnson & Johnson Deepens its Long-Term Commitment to Hong Kong Through OASES Strategic Enterprise Collaboration PR Newswire
Building on more than five decades in Hong Kong, Johnson & Johnson is committed to advancing better health through science, innovation and collaboration for patients and communities in Hong Kong.
Get started
Create a free account to read the full story.